Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

NCT01025453 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: Temsirolimus and Sorafenib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]